GO:0033539 fatty acid beta-oxidation using acyl-CoA dehydrogenase: Mitochondrial Energy Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033539 describes the mitochondrial fatty acid beta-oxidation pathway in which acyl-CoA dehydrogenase catalyzes the initial oxidation step, transferring electrons to the respiratory chain and producing H2O.
• This process shortens fatty acyl-CoAs by two carbons per cycle, generating acetyl-CoA (or propionyl-CoA) and reducing equivalents that drive ATP synthesis.
• Defects in acyl-CoA dehydrogenases cause inherited fatty acid oxidation disorders, including MCAD deficiency and VLCAD deficiency, with hypoglycemia, cardiomyopathy, and sudden death [1,6,8].
• Long-chain fatty acid oxidation deficiency subtly affects the adult heart, detectable by magnetic resonance imaging even in subclinical cases.
• Mitochondrial fatty acid oxidation in alveolar epithelial cells mitigates neutrophilic inflammation during lung injury, linking this pathway to immune regulation.
• Nutritional and metabolic interventions, such as heptanoate supplementation, can partially compensate for long-chain fatty acid oxidation defects.
Description
Fatty acid beta-oxidation using acyl-CoA dehydrogenase (GO:0033539) is the principal mitochondrial pathway for breaking down fatty acids to generate energy. In this process, acyl-CoA dehydrogenase enzymes catalyze the first oxidation step of each cycle, converting an acyl-CoA to a trans-2-enoyl-CoA while transferring electrons to the respiratory chain, ultimately reducing oxygen to water. This pathway is essential for energy homeostasis, especially during fasting, and its dysfunction leads to a group of inherited metabolic diseases known as fatty acid oxidation disorders [1,8]. Researchers study GO:0033539 to understand mitochondrial energy metabolism, to model metabolic disease, and to identify therapeutic targets. The pathway is also increasingly recognized for its roles beyond ATP production, including regulation of inflammation and cellular stress responses.
fatty acid beta-oxidation using acyl-CoA dehydrogenase At A Glance
| GO ID | GO:0033539 |
|---|---|
| GO term | fatty acid beta-oxidation using acyl-CoA dehydrogenase |
| Ontology | biological_process |
| Synonym | mitochondrial fatty acid beta-oxidation |
| Major function | Oxidation of acyl-CoA to trans-2-enoyl-CoA with electron transfer to the respiratory chain |
| End products | Acetyl-CoA (two carbons) or propionyl-CoA (three carbons) |
| Subcellular location | Mitochondrial matrix |
| Key enzymes | Acyl-CoA dehydrogenases (e.g., MCAD, LCAD, VLCAD) |
| Associated diseases | Fatty acid oxidation disorders, cardiomyopathy, hypoglycemia |
What Is GO:0033539?
GO:0033539 is a biological process term describing a fatty acid beta-oxidation pathway in which the initial step of each oxidation cycle, the conversion of an acyl-CoA to a trans-2-enoyl-CoA, is catalyzed by acyl-CoA dehydrogenase. The electrons removed during this oxidation pass through the respiratory chain to oxygen, leaving H2O as the product. The pathway begins with the addition of coenzyme A to a fatty acid and ends when only two or three carbons remain, as acetyl-CoA or propionyl-CoA respectively.
Why Is fatty acid beta-oxidation using acyl-CoA dehydrogenase Important in Cell Biology?
GO:0033539 is fundamental to mitochondrial energy production, particularly during fasting or prolonged exercise when fatty acids become the primary fuel source. Defects in this pathway cause a spectrum of diseases ranging from severe neonatal cardiomyopathy to adult-onset rhabdomyolysis, and they are important causes of sudden infant death [1,6,8]. Beyond energy metabolism, this pathway influences inflammatory responses in lung injury and may modulate cardiac function even in subclinical deficiency states [2,3]. Understanding its regulation and genetic basis is therefore critical for diagnosis, newborn screening, and development of targeted therapies.
• Provides a major source of ATP during fasting and sustained exercise.
• Dysfunction causes inherited fatty acid oxidation disorders with hypoglycemia and cardiomyopathy [1,8].
• Medium-chain acyl-CoA dehydrogenase deficiency is a common inherited metabolic disorder.
• Very-long-chain acyl-CoA dehydrogenase deficiency shows clear genotype-phenotype correlation.
• Long-chain fatty acid oxidation defects can cause subclinical cardiac abnormalities in adults.
• Alveolar epithelial fatty acid oxidation mitigates neutrophilic lung inflammation.
• Nutritional interventions like heptanoate can improve glucose homeostasis in oxidation defects.
• Food withdrawal unmasks energy expenditure defects in long-chain fatty acid oxidation-deficient models.
• Newborn screening and genetic testing rely on understanding this pathway's enzymes.
• The pathway is a target for metabolic engineering and drug discovery.
What Happens During fatty acid beta-oxidation using acyl-CoA dehydrogenase?
Activation and Transport of Fatty Acids
In simple terms: Fatty acids must be activated and shuttled into mitochondria before they can be burned for energy.
Fatty acids are first activated to acyl-CoA in the cytosol. For long-chain fatty acids, the acyl group is transferred to carnitine and transported into the mitochondrial matrix via the carnitine shuttle. Once inside, the acyl-CoA is regenerated and becomes a substrate for beta-oxidation.
First Oxidation by Acyl-CoA Dehydrogenase
In simple terms: The first step removes electrons from the fatty acid chain, creating a double bond.
Acyl-CoA dehydrogenase catalyzes the oxidation of acyl-CoA to trans-2-enoyl-CoA. This reaction transfers electrons to FAD, which then passes them to electron-transferring flavoprotein and ultimately to the respiratory chain, reducing oxygen to water. This is the defining step of GO:0033539.
Hydration, Second Oxidation, and Thiolysis
In simple terms: The fatty acid chain is further processed to shorten it by two carbons and produce acetyl-CoA.
The trans-2-enoyl-CoA is hydrated by enoyl-CoA hydratase to 3-hydroxyacyl-CoA, which is then oxidized by 3-hydroxyacyl-CoA dehydrogenase to 3-ketoacyl-CoA. Finally, thiolase cleaves 3-ketoacyl-CoA to yield acetyl-CoA and an acyl-CoA shortened by two carbons, which re-enters the cycle.
Chain Length Specificity and End Products
In simple terms: Different enzymes handle fatty acids of different lengths, and the cycle ends with acetyl-CoA or propionyl-CoA.
Acyl-CoA dehydrogenases exhibit chain-length specificity: very-long-chain, long-chain, medium-chain, and short-chain enzymes act on corresponding acyl-CoAs. The cycle repeats until only two or three carbons remain, producing acetyl-CoA or propionyl-CoA, respectively. These products enter the citric acid cycle or other metabolic pathways.
Key Genes Involved in GO:0033539 fatty acid beta-oxidation using acyl-CoA dehydrogenase
The following genes encode enzymes and transporters directly involved in mitochondrial fatty acid beta-oxidation using acyl-CoA dehydrogenase.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACADVL | Very-long-chain acyl-CoA dehydrogenase; oxidizes long-chain acyl-CoAs | Mutations cause VLCAD deficiency with cardiomyopathy and hypoglycemia [6,8] |
| ACADM | Medium-chain acyl-CoA dehydrogenase; oxidizes medium-chain acyl-CoAs | Deficiency is a common inherited metabolic disorder |
| ACADS | Short-chain acyl-CoA dehydrogenase; oxidizes short-chain acyl-CoAs | Associated with short-chain acyl-CoA dehydrogenase deficiency |
| ACADL | Long-chain acyl-CoA dehydrogenase; oxidizes long-chain acyl-CoAs | Studied in fatty acid oxidation disorders |
| HADHA | Trifunctional protein subunit alpha; catalyzes hydratase and dehydrogenase steps | Mutations cause long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency |
| HADHB | Trifunctional protein subunit beta; catalyzes thiolase step | Mutations cause trifunctional protein deficiency |
| CPT1A | Carnitine palmitoyltransferase 1A; rate-limiting for mitochondrial fatty acid import | Defects cause CPT1A deficiency with hypoketotic hypoglycemia |
| CPT2 | Carnitine palmitoyltransferase 2; involved in carnitine shuttle | Defects cause CPT2 deficiency with rhabdomyolysis |
| SLC25A20 | Carnitine-acylcarnitine translocase; transports acylcarnitines into mitochondria | Defects cause carnitine-acylcarnitine translocase deficiency |
| ETFA | Electron-transferring flavoprotein alpha subunit; accepts electrons from acyl-CoA dehydrogenases | Defects cause glutaric acidemia type II |
| ETFB | Electron-transferring flavoprotein beta subunit; accepts electrons from acyl-CoA dehydrogenases | Defects cause glutaric acidemia type II |
| ETFDH | Electron-transferring flavoprotein dehydrogenase; transfers electrons to ubiquinone | Defects cause glutaric acidemia type II and riboflavin-responsive disorders |
| ACAA2 | Mitochondrial thiolase; catalyzes final cleavage step | Studied in ketogenesis and fatty acid oxidation |
| HADH | Hydroxyacyl-CoA dehydrogenase; catalyzes second oxidation step | Defects cause hyperinsulinism and fatty acid oxidation disorders |
| ECHS1 | Enoyl-CoA hydratase; catalyzes hydration step | Defects cause ECHS1 deficiency with neurological symptoms |
| PPARA | Peroxisome proliferator-activated receptor alpha; regulates fatty acid oxidation genes | Target for modulating fatty acid oxidation |
| PGC1A | PPAR gamma coactivator 1 alpha; promotes mitochondrial biogenesis and fatty acid oxidation | Key regulator of energy metabolism |
How Is fatty acid beta-oxidation using acyl-CoA dehydrogenase Regulated?
Fatty acid beta-oxidation using acyl-CoA dehydrogenase is regulated at multiple levels. The PPAR alpha (PPARA) nuclear receptor and its coactivator PGC1A control the expression of many genes encoding acyl-CoA dehydrogenases and auxiliary enzymes, especially during fasting. Malonyl-CoA inhibits carnitine palmitoyltransferase 1 (CPT1), preventing fatty acid entry into mitochondria when glucose is abundant. Hormonal signals such as glucagon and insulin reciprocally regulate the pathway. Additionally, substrate availability and redox state influence flux through the pathway.
fatty acid beta-oxidation using acyl-CoA dehydrogenase and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACADM | Medium-chain acyl-CoA dehydrogenase deficiency | Acadm knockout mouse; patient-derived fibroblasts |
| ACADVL | Very-long-chain acyl-CoA dehydrogenase deficiency | Acadvl knockout mouse; induced pluripotent stem cell-derived cardiomyocytes |
| HADHA | Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency | Hadha knockout mouse; patient cell lines |
| CPT2 | Carnitine palmitoyltransferase II deficiency | Cpt2 knockout mouse; muscle-specific knockout |
| ETFDH | Glutaric acidemia type II | Etfdh knockout mouse; patient fibroblasts |
Inherited Fatty Acid Oxidation Disorders
Mutations in genes encoding acyl-CoA dehydrogenases or associated proteins cause a group of inherited metabolic diseases. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is one of the most common, presenting with hypoketotic hypoglycemia, vomiting, and lethargy during fasting. Very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency can cause severe cardiomyopathy, hypoglycemia, and sudden death, with a clear genotype-phenotype correlation [6,8]. Management includes dietary avoidance of fasting and supplementation with medium-chain triglycerides.
Cardiac Involvement in Long-Chain Fatty Acid Oxidation Defects
Long-chain fatty acid oxidation deficiencies can affect the adult heart even in subclinical forms. A case-control magnetic resonance study found subtle cardiac functional and metabolic alterations in adults with long-chain fatty acid oxidation defects. This highlights the importance of cardiac monitoring in these patients.
Fatty Acid Oxidation in Inflammation and Lung Injury
Mitochondrial fatty acid oxidation in alveolar epithelial cells plays a role in mitigating neutrophilic inflammation during lung injury. Enhancing fatty acid oxidation in these cells may represent a therapeutic strategy for inflammatory lung diseases.
Metabolic Compensation and Therapeutic Approaches
In long-chain fatty acid oxidation defects, alternative substrates such as heptanoate can improve compensatory glucose homeostasis, suggesting that nutritional interventions may benefit patients. Food withdrawal studies in mouse models have shown reduced energy expenditure and inactivity, providing insights into metabolic adaptations.
From fatty acid beta-oxidation using acyl-CoA dehydrogenase-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ACADM cause fasting hypoglycemia? | ACADM knockout mouse |
| Can a specific point mutation in ACADVL mimic human cardiomyopathy? | ACADVL point-mutation knock-in mouse |
| Does overexpression of PGC1A enhance fatty acid oxidation? | PGC1A overexpression cell line |
| How does a tagged ACADVL protein localize in mitochondria? | ACADVL tagged knock-in cell line |
| What is the effect of a patient-derived mutation on enzyme activity? | Patient-derived fibroblasts or iPSCs |
| Can CRISPR activation of ACADVL rescue lipid accumulation? | CRISPR activation (dCas9-VP64) in hepatocytes |
How to Study the fatty acid beta-oxidation using acyl-CoA dehydrogenase Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression levels | Assessing pathway gene expression in disease models |
| Proteomics | Protein abundance and modifications | Quantifying acyl-CoA dehydrogenase enzymes |
| Metabolomics | Acylcarnitine and metabolite levels | Diagnosing fatty acid oxidation disorders |
| Enzyme activity assay | Catalytic activity of acyl-CoA dehydrogenases | Validating patient mutations |
| Magnetic resonance imaging | Cardiac structure and function | Detecting subclinical cardiac involvement |
| CRISPR screening | Genes required for fatty acid oxidation | Identifying novel regulators |
| Western blot | Protein expression | Confirming knockout or overexpression |
Genomic and Transcriptomic Approaches
RNA sequencing (RNA-seq) can quantify expression of genes involved in fatty acid beta-oxidation, such as ACADM, ACADVL, and PPARA, under different metabolic conditions. Single-cell RNA-seq can reveal cell-type-specific expression in tissues like heart and lung.
Proteomic and Metabolomic Profiling
Mass spectrometry-based proteomics can measure protein levels of acyl-CoA dehydrogenases, while metabolomics can quantify acylcarnitines and other intermediates to assess pathway flux. These methods are used to diagnose fatty acid oxidation disorders.
Enzyme Activity Assays
Acyl-CoA dehydrogenase activity can be measured in cell or tissue lysates using spectrophotometric assays that follow the reduction of electron acceptors. Such assays are valuable for validating genetic variants found in patients.
Imaging and Functional Studies
Magnetic resonance imaging (MRI) and spectroscopy can detect cardiac and metabolic abnormalities in patients with fatty acid oxidation defects. In cells, fluorescently tagged proteins and live-cell imaging can track mitochondrial morphology and dynamics.
How CRISPR Can Be Used to Study GO:0033539 fatty acid beta-oxidation using acyl-CoA dehydrogenase
Knockout
CRISPR knockout of genes such as ACADM or ACADVL in cell lines or animal models can recapitulate fatty acid oxidation deficiency. These models are used to study metabolic adaptations, cardiac dysfunction, and responses to fasting.
Point Mutation
Introducing patient-specific point mutations (e.g., in ACADVL) via CRISPR prime editing or homology-directed repair allows researchers to study genotype-phenotype correlations and test targeted therapies.
Knock-in
Knock-in of reporter tags (e.g., GFP) or epitope tags into endogenous acyl-CoA dehydrogenase genes enables real-time tracking of protein localization and interactions in mitochondria.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes like PGC1A or ACADVL can enhance fatty acid oxidation and is used to test whether boosting the pathway rescues disease phenotypes.
How EDITGENE Supports fatty acid beta-oxidation using acyl-CoA dehydrogenase Research
Researchers studying fatty acid beta-oxidation using acyl-CoA dehydrogenase-related genes often need to determine whether a candidate gene is causally involved in metabolic phenotypes, and to dissect the molecular mechanisms of disease-associated variants. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for fatty acid beta-oxidation using acyl-CoA dehydrogenase research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ACAD10 Knockout HEK293 Cell Line | EDJ-KQ2319 | Human | 80724 | Details Get a Quote |
| ACADM Knockout HEK293 Cell Line | EDJ-KQ3144 | Human | 34 | Details Get a Quote |
| ACADL Knockout HEK293 Cell Line | EDJ-KQ3148 | Human | 33 | Details Get a Quote |
| ACADVL Knockout HEK293 Cell Line | EDJ-KQ3277 | Human | 37 | Details Get a Quote |
| ETFDH Knockout HEK293 Cell Line | EDJ-KQ3814 | Human | 2110 | Details Get a Quote |
| ACADS Knockout HEK293 Cell Line | EDJ-KQ3992 | Human | 35 | Details Get a Quote |
| ETFA Knockout HEK293 Cell Line | EDJ-KQ4558 | Human | 2108 | Details Get a Quote |
| GCDH Knockout HEK293 Cell Line | EDJ-KQ4688 | Human | 2639 | Details Get a Quote |
| IVD Knockout HEK293 Cell Line | EDJ-KQ5012 | Human | 3712 | Details Get a Quote |
| ACAD11 Knockout HEK293 Cell Line | EDJ-KQ9989 | Human | 84129 | Details Get a Quote |
| GCDH Knockout A-549 Cell Line | EDJ-KQ26152 | Human | 2639 | Details Get a Quote |
| ETFA Knockout A-549 Cell Line | EDJ-KQ27199 | Human | 2108 | Details Get a Quote |
| ETFA Knockout HCT 116 Cell Line | EDJ-KQ27200 | Human | 2108 | Details Get a Quote |
| ETFA Knockout HeLa Cell Line | EDJ-KQ27201 | Human | 2108 | Details Get a Quote |
| ETFDH Knockout A-549 Cell Line | EDJ-KQ27202 | Human | 2110 | Details Get a Quote |
Displaying Records 1 To 15 Of 45 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About fatty acid beta-oxidation using acyl-CoA dehydrogenase
What is fatty acid beta-oxidation using acyl-CoA dehydrogenase?
It is a mitochondrial pathway that breaks down fatty acids to produce energy, defined by the initial oxidation step catalyzed by acyl-CoA dehydrogenase.
What genes are involved in fatty acid beta-oxidation using acyl-CoA dehydrogenase?
Key genes include ACADVL, ACADM, ACADS, ACADL, HADHA, HADHB, CPT1A, CPT2, and SLC25A20, among others [1,6,8].
What diseases are associated with defects in this pathway?
Defects cause fatty acid oxidation disorders such as MCAD deficiency, VLCAD deficiency, and CPT2 deficiency, leading to hypoglycemia, cardiomyopathy, and rhabdomyolysis [1,6,8].
How is fatty acid beta-oxidation regulated?
It is regulated by PPARA, PGC1A, malonyl-CoA inhibition of CPT1, and hormonal signals like glucagon and insulin.
What is the role of acyl-CoA dehydrogenase in this process?
Acyl-CoA dehydrogenase catalyzes the first oxidation step, converting acyl-CoA to trans-2-enoyl-CoA and transferring electrons to the respiratory chain.
Can CRISPR be used to study fatty acid oxidation disorders?
Yes, CRISPR knockout, point mutation, and knock-in models are widely used to study gene function and disease mechanisms [6,7].
What are the symptoms of medium-chain acyl-CoA dehydrogenase deficiency?
Symptoms include hypoketotic hypoglycemia, vomiting, lethargy, and risk of sudden death during fasting.
How does long-chain fatty acid oxidation deficiency affect the heart?
It can cause cardiomyopathy and subclinical cardiac abnormalities detectable by MRI [3,6].
What is the role of fatty acid oxidation in lung inflammation?
Alveolar epithelial fatty acid oxidation mitigates neutrophilic inflammation in lung injury.
What treatments are available for fatty acid oxidation disorders?
Management includes avoiding fasting, dietary medium-chain triglyceride supplementation, and in some cases heptanoate or other experimental therapies [4,8].
Conclusion
GO:0033539 fatty acid beta-oxidation using acyl-CoA dehydrogenase is a central mitochondrial pathway for energy production and metabolic homeostasis. Its dysfunction causes a range of inherited disorders with significant morbidity and mortality, and it is increasingly implicated in inflammation and cardiac function. Continued research using CRISPR models and multi-omics approaches will deepen our understanding and aid in developing new therapies.
References
- 1. Mason E et al.. 2023. Medium-chain Acyl-COA dehydrogenase deficiency: Pathogenesis, diagnosis, and treatment.. Endocrinol Diabetes Metab 6(1):e385 PMID: 36300606
- 2. Chung KP et al.. 2024. Alveolar epithelial cells mitigate neutrophilic inflammation in lung injury through regulating mitochondrial fatty acid oxidation.. Nat Commun 15(1):7241 PMID: 39174557
- 3. Knottnerus SJG et al.. 2020. Subclinical effects of long-chain fatty acid β-oxidation deficiency on the adult heart: A case-control magnetic resonance study.. J Inherit Metab Dis 43(5):969-980 PMID: 32463482
- 4. Nurjanah S et al.. 2023. Heptanoate Improves Compensatory Mechanism of Glucose Homeostasis in Mitochondrial Long-Chain Fatty Acid Oxidation Defect.. Nutrients 15(21) PMID: 37960342
- 5. Eaton S et al.. 1996. Mammalian mitochondrial beta-oxidation.. Biochem J 320 ( Pt 2)(Pt 2):345-57 PMID: 8973539
- 6. Andresen BS et al.. 1999. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency.. Am J Hum Genet 64(2):479-94 PMID: 9973285
- 7. Diekman EF et al.. 2014. Food withdrawal lowers energy expenditure and induces inactivity in long-chain fatty acid oxidation-deficient mouse models.. FASEB J 28(7):2891-900 PMID: 24648546
- 8. Yamada K et al.. 2019. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.. J Hum Genet 64(2):73-85 PMID: 30401918
